Navigation Links
BioMarin Announces FDA Approval for Kuvan
Date:12/13/2007

ired for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. Currently, PKU can only be managed by a Phe-restricted diet, which is supplemented by nutritional replacement products, like formulas and specially-manufactured foods; however, the strict diet is difficult for most patients to adhere to the extent needed for achieving adequate control of blood Phe levels. To learn more about PKU, please visit http://www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the trea
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... ENCINO, Calif. , June 1, 2015  Research ... to scientific, technical and medical (STM) information for life ... has been invited to present at the LD Micro ... Luxe Hotel in Los Angeles ... scheduled to present on Wednesday, June 3rd at 9:30 ...
(Date:6/1/2015)... 1, 2015  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... known as ,nal-IRI, in a Phase 1 investigator-sponsored study ... glioma. Data were presented at the 2015 American Society ... Chicago, IL. Results from this study show ... high-grade glioma when given intravenously.  Based in ...
(Date:6/1/2015)... , June 1, 2015 ... weight over large area and improve the quality life ... ulcer. These devices play a significant role in inhibiting ... reduce the need to turn or rotate an immobile ... include mattress, mattresses overlay, and specialty beds. These devices ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3
... Inc. (NYSE: WST ) today announced that Donald E. ... Federici, Chief Financial Officer, will attend the Lazard Capital Markets ... present an overview of West,s business and outlook on Tuesday, ... of the corporate presentation document as well as a live ...
... Ill., Nov. 12 Nearly one in three adult Americans ... 34 million have low HDL "good" cholesterol levels. To ... Abbott has launched two Web sites: www.knowyourhdl.com ... triglyceride and low HDL levels are factors that can raise ...
Cached Medicine Technology:New Web Sites Educate About Triglycerides and HDL Cholesterol 2
(Date:6/1/2015)... 02, 2015 The National Association ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in business. NAPW is the ... more than 700,000 members and over 200 operating Local ... important honor,” said NAPW President Star Jones. “Her perseverance, ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Carson Energy ... facilitate their investors IRA transactions. AdvantaIRA Trust, LLC is ... investors the ability to fund positions using IRA’s does ... participate on a project, even if there current cash ... an additional funding source for Carson and their investors ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 The Delta ... health programs and organizations in Michigan, Ohio and Indiana ... deadline of Sept. 30, 2015 has been set. , ... in grants to organizations that specifically focus on children’s ... primarily address oral health in adults. Each grant request ...
(Date:6/1/2015)... June 01, 2015 EBSCO Health ... today introduced DynaMed Plus™ , a cross-platform evidence-based ... professionals. It provides clinicians with the ideal blend of ... care paths. , DynaMed Plus is a significant ... includes the most frequently updated evidence-based content. DynaMed Plus ...
(Date:6/1/2015)... KC and Monica Craichy, Founders of ... best superfood products in the world to ... , "Monica and I are excited to be ... Living Fuel Super Meals - SuperBerry®, SuperGreens and LivingProtein® ... Texas," KC Craichy said. "We have attempted to do ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Brighter Futures Community Grants Program Seeks to Help Fund Local Oral Health Programs 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3
... bone marrow, and known as MAPCs, have proved to ... and also in muscle tissue when treating peripheric vascular ... mouse models by two research groups, one by the ... Applied Medical Research (CIMA), also of the University of ...
... font of all knowledge, despite the plethora of information ... of New South Wales (UNSW) in Australia have found ... of useful materials, people pay more attention to information ... read the right material, they are stubborn to changing ...
... continuing operations, excluding ... guidance for full fiscal year 2008 earnings per share from, continuing operations, excluding specified ... ... N.J., Jan. 24 BD (Becton,Dickinson and Company) (NYSE: BDX ) today reported ...
... Allergy Friendly" Certification Now Available, WASHINGTON, ... product Certification Program administered by the,Asthma and ... with the,international research organization, Allergy Standards Limited ... & allergy friendly(TM) products., (Photo: ...
... formulation temporarily reserved for patients with Acute Myelogenous Leukemia ... transplantation graft failure or ... aims to restore US supplies ... WAYNE, N.J., Jan. 23 Bayer HealthCare Pharmaceuticals,Inc. announced today, ...
... Pa., Jan. 23 Pennsylvania,AFL-CIO President William George ... the latest decisions by,Representatives John Peterson, Joseph Pitts, ... insurance for millions of children in,families hit hardest ... see how, in the face of a severe ...
Cached Medicine News:Health News:Adult stem cell application effective in treatment of peripheric vascular disease 2Health News:Adult stem cell application effective in treatment of peripheric vascular disease 3Health News:Why the Web tells us what we already know 2Health News:BD Announces Results For First Fiscal Quarter 2Health News:BD Announces Results For First Fiscal Quarter 3Health News:BD Announces Results For First Fiscal Quarter 4Health News:BD Announces Results For First Fiscal Quarter 5Health News:BD Announces Results For First Fiscal Quarter 6Health News:BD Announces Results For First Fiscal Quarter 7Health News:BD Announces Results For First Fiscal Quarter 8Health News:BD Announces Results For First Fiscal Quarter 9Health News:BD Announces Results For First Fiscal Quarter 10Health News:Asthma Foundation Expands Certification Program to be 'Friendly' to Millions More 2Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 2Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 3Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 4Health News:Pennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Children's Health Care 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: